At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Axel Hauschild presented data from a Phase III multicenter clinical trial that found treatment with the investigational BRAF-targeted drug dabrafenib reduced the risk of disease progression by 70 percent compared to standard dacarbazine chemotherapy in patients with previously untreated, advanced melanoma with mutations in the BRAF gene.